Zai Lab Limited (ZLAB) Announces Proposed 5.5M ADS Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Zai Lab Announces Proposed Public Offering of American Depositary Shares
January 21, 2020 4:33 PM ESTSHANGHAI, China, and SAN FRANCISCO, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,500,000 American depositary shares (ADSs), each representing one ordinary share of the Company (the Primary ADS Offering). In addition, QM11 Limited, a shareholder of the Company, intends to offer 500,000 ADSs of the Company (the Secondary ADS Offering and together with the Primary ADS Offering, the Offering). Zai Lab and QM11 Limited expect to grant the underwriters... More



